Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Dr Lalchandani Labs Ltd - 541299 - Intimation Of Board Meeting To Be Held On 04Th September 2019

 This is to inform you that the meeting of the Board of Directors of the Company will be held on Wednesday, 04th September 2019 at 4.00 p.m.at Registered Office at M-20, Greater Kailash,Part-1,South Delhi-110048 to transact the followings Business 1.To grant leave of absence, if any, to the Directors; 2.To take on record the minutes of previous board meeting held on 24th August 2019; 3.To consider and approve Balance Sheet,Profit and Loss Account,notes and schedules forming part of Financial Statements and cash flow statement as per Companies Act, 2013 for the year ended 31st March 2019; 4.To approve the draft Board''s Report for the FY 2018-2019; 5.To consider and approve draft notice of forthcoming Annual General meeting(AGM) of the company and fixation of day,time,date and venue of Annual General Meeting; 6.To consider and decide cut-off date/record date for the dispatch of notice and Annual Report for FY 2018-2019; 7.To consider any other matter with the permission of the chair.
27-08-2019
Bigul

Dr Lalchandani Labs Ltd - 541299 - Intimation Regarding Appointment As Secretarial Auditor And Scrutinizer.

 Intimation is hereby given that Dr Lalchandani Labs Limited has appointed Mr. Vikram Grover of M/S. Vikram Grover & Company as its Secretarial Auditor and Scrutinizer for Financial Year 2018-2019 in a meeting of Board of Directors held on 24th August, 2019.
24-08-2019
Bigul

Dr Lalchandani Labs Ltd - 541299 - Announcement Regarding Tie Up With Express Clinic Centres In Delhi/NCR

 This is to bring in the kind attention of all the stakeholders that in an attempt to increase our operational revenue we have entered into an agreement for rendering diagnostic services to Express Clinic Pvt Ltd, having its address at C-11, basement Lajpat Nagar-3, a corporate chain of Medical laboratories and doctor consultation having pan india presence. We expect to generate a renevue of approx. Rs. 84 Lakhs per annum by rendering diagnostic services to this prestigious client.
22-07-2019
Bigul

Dr Lalchandani Labs Ltd - 541299 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 In accordance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2019, based on the certificate received from Cameo Corporate Service Limited (RTA), which is enclosed herewith, we hereby confirm that within 30 days of receipt of the securities received for dematerialization that: a) The securities comprised in the said Certificate(s) of Security have been listed on the Stock Exchanges; and b) The said Certificate(s) after due verification has been mutilated and canceled and the name of the depository has been substituted in our records as the registered owner. Kindly take the same on your records.
20-07-2019
Bigul

Dr Lalchandani Labs Ltd - 541299 - Statement Of Investor Complaints For The Quarter Ended June 2019

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- SWATI PODDARDesignation :- Company Secretary and Compliance Officer
03-07-2019
Bigul

Dr Lalchandani Labs Ltd - 541299 - Announcement Regarding Tie Up'S With Aastha Hospital & IVF Centre.

 This is to bring in the kind attention of all the stakeholders that in an attempt to increase our operational revenue we have entered into an agreement for rendering diagnostic services at Aastha Hospital & IVF Centre at Outer Ring Road, New Delhi. Aastha Hospital & IVF Centre is a 55 bedded hospital with its specialization in IVF, Gynaecology, Paediatrics and other speciality & super speciality services. We expects to generate a revenue of approx. Rs. 60.00 Laks per annum by rendering diagnostic services to this prestigious client.
26-06-2019
Bigul

Dr Lalchandani Labs Ltd - 541299 - Audited Financial Results For The Half Year And Year Ended March 31, 2019

 In continuation of our Letter dated May 23, 2019, we wish to inform you that the Board of the Company at its meeting held today, inter alia has transacted the following: a) The Board has approved the Audited Financial Results for the half year and year ended March 31, 2019. Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we enclose the following: i. Statement showing Audited Financial Results for the half year and year ended March 31, 2019. ii. Auditors Report on Financial Results of the Company for the year ended 31st March, 2019. Kindly take the same on record and acknowledge.
30-05-2019
Bigul

Dr Lalchandani Labs Ltd - 541299 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayDr Lalchandani Labs Ltd 2CINU85320DL2017PLC321605 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY 0 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: SWATIPODDAR Designation: COMPANYSECREATRYANDCOMPLIANCEOFFICER EmailId: [email protected] Name of the Chief Financial Officer: HIMANSHUMISHRA Designation: CHIEFFINANCIALOFFICER EmailId: [email protected] Date: 29/05/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
29-05-2019
Bigul

Dr Lalchandani Labs Ltd - 541299 - Intimation Of Appointment Of Company Secretary And Compliance Officer Of The Company.

 This is to inform you that Ms. Swati Poddar, an Associate Member of the Institute of Company Secretaries of India holding Membership no-58616, has been appointed as Company Secretary & Compliance Officer of the Company with effect from 23rd May, 2019 in terms of Companies Act, 2013 and Rules framed there under and pursuant to Regulation 6 of SEBI (LODR) Regulations, 2015. Further to inform that Ms. Swati Poddar, also designated as KMP under section 203 of the Companies Act, 2013. Kindly take the above information on record.
29-05-2019
Bigul

Dr Lalchandani Labs Ltd - 541299 - Board Meeting Intimation for Intimation Of The Board Meeting Of The Company To Be Held On 30/05/2019

 Dr Lalchandani Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2019 ,inter alia, to consider and approve 1. Audited Financial Results of the Company for the Year ended 31st March, 2019 along with Limited Review report. 2.Any other Business matter, with the permission of the Chair.
23-05-2019
Next Page
Close

Let's Open Free Demat Account